Merck and Moderna Report Major Success in Personalized Melanoma Vaccine Trial

Merck and Moderna announced Thursday that their personalized mRNA vaccine for melanoma reduced the risk of death or recurrence by 42 percent compared to standard care. This significant finding emerged from a late-stage trial involving over a thousand patients. The companies stated they are already working with regulatory authorities to move toward approval for the new treatment option.

The announcement follows an earlier report in August when the partners confirmed the vaccine had succeeded but withheld specific details. They planned to share the full data at the European Society of Medical Oncology conference currently taking place in Madrid, Spain. However, an oncology news site broke the embargo by reporting the results early. Consequently, the companies released the top-line numbers ahead of the scheduled Saturday presentation. The complete data has been accepted for publication in the New England Journal of Medicine.

The trial involved 1,137 patients diagnosed with stage IIB to IV melanoma. All participants had already undergone surgery to remove their tumors before joining the study. Researchers randomly assigned these individuals to one of two groups in a 2-to-1 ratio. One group received a combination therapy consisting of the personalized mRNA vaccine alongside the standard treatment. The other group received only the standard treatment, which was Merck’s monoclonal antibody drug Keytruda.

Moderna CEO Stéphane Bancel emphasized the company's long-standing belief in the power of mRNA technology. He noted that the goal has always been to create cancer treatments uniquely matched to each patient’s specific tumor. Bancel described these results as a defining moment for that vision. He added that the findings show what is possible when the industry rethinks how medicines are made and reinforced the conviction that mRNA can fundamentally change cancer treatment.

This success marks a significant advance in treating melanoma, which is known as the deadliest form of skin cancer. More broadly, the results bolster hope for a new paradigm in oncology. It suggests that mRNA vaccines and individualized cancer-targeting medicines may offer a powerful new approach to therapy. For patients in the Southwest and beyond, this represents a tangible step forward in the fight against aggressive skin cancers.

The companies are now focused on the next steps in the regulatory process. While the full conference presentation is still expected, the early release of key statistics has generated immediate attention. The data supports the idea that combining established immune checkpoint inhibitors with personalized vaccines can yield better outcomes than either approach alone. This development is likely to influence future treatment guidelines for advanced melanoma patients.